74 related articles for article (PubMed ID: 21790004)
21. A melanosomal membrane protein is a cell surface target for melanoma therapy.
Takechi Y; Hara I; Naftzger C; Xu Y; Houghton AN
Clin Cancer Res; 1996 Nov; 2(11):1837-42. PubMed ID: 9816138
[TBL] [Abstract][Full Text] [Related]
22. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
23. Ovarian tumour antigens as potential targets for immune gene therapy.
Kuiper M; Peakman M; Farzaneh F
Gene Ther; 1995 Jan; 2(1):7-15. PubMed ID: 7712335
[TBL] [Abstract][Full Text] [Related]
24. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development.
Wiznerowicz M; Fong AZ; Mackiewicz A; Hawley RG
Gene Ther; 1997 Oct; 4(10):1061-8. PubMed ID: 9415312
[TBL] [Abstract][Full Text] [Related]
25. [An immunocytochemical investigation of antigen expression by skin melanoma cells cultured for vaccine production].
Moiseenko VM; Danilova AB; Danilov AO; Turkevich EA; Baldueva IA; Matsko DE
Vopr Onkol; 2008; 54(3):303-14. PubMed ID: 18652234
[TBL] [Abstract][Full Text] [Related]
26. T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.
Coccoris M; Straetemans T; Govers C; Lamers C; Sleijfer S; Debets R
Expert Opin Biol Ther; 2010 Apr; 10(4):547-62. PubMed ID: 20146634
[TBL] [Abstract][Full Text] [Related]
27. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells.
Sanchez-Perez L; Gough M; Qiao J; Thanarajasingam U; Kottke T; Ahmed A; Thompson JM; Maria Diaz R; Vile RG
Gene Ther; 2007 Jul; 14(13):998-1009. PubMed ID: 17443216
[TBL] [Abstract][Full Text] [Related]
28. [Gene therapy applied to melanoma].
Dreno B
Ann Dermatol Venereol; 1995; 122(4):235-40. PubMed ID: 8526418
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma.
Eberle J; Fecker LF; Hossini AM; Kurbanov BM; Fechner H
Exp Dermatol; 2008 Jan; 17(1):1-11. PubMed ID: 18095940
[TBL] [Abstract][Full Text] [Related]
30. Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies.
Tímár J; Mészáros L; Ladányi A; Puskás LG; Rásó E
Cell Immunol; 2006 Dec; 244(2):154-7. PubMed ID: 17433276
[TBL] [Abstract][Full Text] [Related]
31. T-cell distribution and adhesion receptor expression in metastatic melanoma.
Weishaupt C; Munoz KN; Buzney E; Kupper TS; Fuhlbrigge RC
Clin Cancer Res; 2007 May; 13(9):2549-56. PubMed ID: 17473183
[TBL] [Abstract][Full Text] [Related]
32. Cell surface antigens of melanocytes and melanoma.
Albino AP; Houghton AN
Cancer Surv; 1985; 4(1):185-211. PubMed ID: 3842314
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
34. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells.
Pietra G; Mortarini R; Parmiani G; Anichini A
Cancer Res; 2001 Nov; 61(22):8218-26. PubMed ID: 11719453
[TBL] [Abstract][Full Text] [Related]
35. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
[TBL] [Abstract][Full Text] [Related]
36. Stem cells in melanoma development.
Sabatino M; Stroncek DF; Klein H; Marincola FM; Wang E
Cancer Lett; 2009 Jul; 279(2):119-25. PubMed ID: 19095348
[TBL] [Abstract][Full Text] [Related]
37. Scientific aspects of gene therapy in melanoma.
Rankin EM
Curr Opin Oncol; 1995 Mar; 7(2):192-6. PubMed ID: 7756385
[TBL] [Abstract][Full Text] [Related]
38. Molecular events in melanoma development and progression.
Meier F; Satyamoorthy K; Nesbit M; Hsu MY; Schittek B; Garbe C; Herlyn M
Front Biosci; 1998 Sep; 3():D1005-10. PubMed ID: 9740553
[TBL] [Abstract][Full Text] [Related]
39. Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention.
Sigalotti L; Covre A; Nicolay HJ; Coral S; Maio M
Cancer Immunol Immunother; 2010 Mar; 59(3):487-8. PubMed ID: 19862522
[No Abstract] [Full Text] [Related]
40. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy.
Smalley KS; Herlyn M
Int J Cancer; 2009 Mar; 124(6):1245-50. PubMed ID: 19089923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
